A couple of key points -
Given the large write downs, there is not much in terms of depreciation and amortization to come.
Interest bill should be between $35-50 m
There is a reasonable line of sight for revenues and profits given that this is a business that is not prone to big shifts in cases or costs.
Debt repayment of $70-100 m p/a should be possible from here on.
Banks are struggling to generate returns on loans atm and will be more than happy to keep this loan going forever so long as it is serviced.
The results are not a surprise on the upside or downside. In fact, it is going to be quite boring from here on, with steady improvement in finances and it will look like any stable business with nice returns in 3-4 yrs.
- Forums
- ASX - By Stock
- SGH
- Ann: FY16 Earnings Guidance-SGH.AX
Ann: FY16 Earnings Guidance-SGH.AX, page-76
-
- There are more pages in this discussion • 383 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SGH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online